Abstract: Objective : To study the correlationship between the serum IL-8 and soluble Apo-1/Fas and the clinicopathological parameters in postoperative breast cancer patients with recurrent and metastatic foci. Methods : Serum IL-8 and soluble Apo-1/Fas (sFas) was measured by enzyme linked immunosorbent assay (ELISA) in 94 recurrent and metastatic breast cancer patients before and after chemotherapy, as compared with 30 healthy controls. Results : (1) Levels of IL-8 and sFas in breast cancer patients were significantly higher than those in healthy controls (P<0.05); (2) Serum IL-8 was correlated with estrogen -receptor (ER) status and bone metastasis: Levels of IL-8 were significantly higher in ER-negative patients compared with ER-positive patients (P<0.05), and in patients with bone metastasis compared to patients with local recurrence and/or regional lymph node metastasis (P<0.01)and patients with liver and/or lung metastasis (P<0.05), respectively. (3) Serum sFas was correlated with menopausal status and liver and/or lung metastasis. Levels of sFas were significantly higher in postmenopausal patients compared with premenopausal patients (P<0.05), and in patients with liver and/or lung metastasis compared with patients with local recurrence and/or rigional lymph node metastasis (P<0.01) and patients with bone metastasis (P<0.05), respectively. (4) Levels of sFas were remarkably reduced in breast cancer patients after chemotherapy (P<0.05), but there is no significant difference in IL-8 level between pretreatment patients and patients after chemotherapy (P >0.05). Conclusion :Serum IL-8 and sFas are correlated with biological behaviors and prognosis in breast cancer patients and deserve further investigation.